Human bone marrow mononuclear cells (BMMNCs) and en-riched CD34 positive (CD34') cells were transduced with ad-enovirus vectors encoding Escherichia coli P-galactosidase gene. Tranductions were carried out by 24-hour coincuba-tion with adenovirus vectors at different multiplicities of in-fections (moil. Efficacy of gene transfer into BM cells and expression of the gene product (ie, P-galactosidase) were studied using X-Gal histochemical staining and flow cytome-tric analysis. X-Gal staining demonstrated that the percent-age of positive cells at mois of 5 to 500 was 3.4 % to 34.5% for BMMNCs and 6.0 % to 20.0 % for enriched CD34+ cells. Similar results (1.5 % to 35.7 % for BMMNCs and 5.4 % to 24.2 % for enriched CD34+ cells) were obtain...
International audienceMacrophages are putative target cells for expressing an exogenous gene with th...
Gaucher disease, a lysosomal glycolipid storage disorder, results from the genetic deficiency of an ...
To initiate our clinical trial for chemotherapy protection, I established the retroviral vector syst...
The ability of lentiviral vectors to transfer genes into human hematopoietic stem cells was studied,...
Mobilized blood CD34+ cells from cancer patients were ex vivo infected by a recombinant adenovirus v...
OBJECTIVES: Lentiviral vectors can transduce nondividing cells. As most haematopoietic stem cells (H...
OBJECTIVES: Lentiviral vectors can transduce nondividing cells. As most haematopoietic stem cells (H...
In order to improve the efficiency of gene transduction into human hematopoietic stem cells by retro...
Human bone marrow (BM) mesenchymal stem/progenitor cells are potentially attractive targets for ex v...
Abstract Background The gene transduction efficiency of adenovirus to hematopoietic cells, especiall...
Adenosine deaminase (ADA) deficiency results in severe combined immune deficiency disease (SCID), wh...
Hematopoietic stem cells (HSCs) are defined by their capacity to self-renew and differentiate into a...
Background: The hematopoietic stem cells have been one of the major targets for designing human gene...
To initiate our clinical trial for chemotherapy protection, I established the retroviral vector syst...
Haematopoietic stem cells (HSCs) are important target cells for gene therapy of blood disorders due ...
International audienceMacrophages are putative target cells for expressing an exogenous gene with th...
Gaucher disease, a lysosomal glycolipid storage disorder, results from the genetic deficiency of an ...
To initiate our clinical trial for chemotherapy protection, I established the retroviral vector syst...
The ability of lentiviral vectors to transfer genes into human hematopoietic stem cells was studied,...
Mobilized blood CD34+ cells from cancer patients were ex vivo infected by a recombinant adenovirus v...
OBJECTIVES: Lentiviral vectors can transduce nondividing cells. As most haematopoietic stem cells (H...
OBJECTIVES: Lentiviral vectors can transduce nondividing cells. As most haematopoietic stem cells (H...
In order to improve the efficiency of gene transduction into human hematopoietic stem cells by retro...
Human bone marrow (BM) mesenchymal stem/progenitor cells are potentially attractive targets for ex v...
Abstract Background The gene transduction efficiency of adenovirus to hematopoietic cells, especiall...
Adenosine deaminase (ADA) deficiency results in severe combined immune deficiency disease (SCID), wh...
Hematopoietic stem cells (HSCs) are defined by their capacity to self-renew and differentiate into a...
Background: The hematopoietic stem cells have been one of the major targets for designing human gene...
To initiate our clinical trial for chemotherapy protection, I established the retroviral vector syst...
Haematopoietic stem cells (HSCs) are important target cells for gene therapy of blood disorders due ...
International audienceMacrophages are putative target cells for expressing an exogenous gene with th...
Gaucher disease, a lysosomal glycolipid storage disorder, results from the genetic deficiency of an ...
To initiate our clinical trial for chemotherapy protection, I established the retroviral vector syst...